Health care stocks have surged in early trade, up more than a per cent.
Biotech company Immuron made the most of the boost, with its shares up more than 21 per cent after posting its Q3 FY23 financial figures.
Global sales of its traveller-focussed digestive-health products, Travelan and Protectyn, gained nearly 240 per cent to $1.4 million thanks to more overseas trips.
Immuron shares are trading at 8.5 cents.
Meanwhile, NSW-based biotech company Noxopharm (NOX) has tumbled more than 42 per cent.
The company announced its decision to prioritise the development of its two preclinical technology platforms moving forward – Chroma and Sofra.
It will discontinue its two Veyonda cancer-treatment trials due to low patient acceptance of suppositories.
The company says the move will better utilise shareholder funds and maximise shareholder value. Company shares fell to 6.3 cents.
Looking to the materials sector and Western Mines Group has seen its shares soar 46 per cent.
The company released initial aqua regia – or ACID – testing results from its Mulga Tank nickel-copper-platinum group element project in the Yilgarn region of Western Australia.
Results point to a high percentage of recoverable nickel in sulphide form, rather than silicate nickel.
The company says the “very positive” results offer encouragement to conduct further metallurgical test work.
Talga Group was also up more than five per cent to $1.71.
The company secured an environmental permit for its Nunasvaara South natural graphite mine in northern Sweden.
The tick of approval was granted in line with the company’s detailed feasibility study and permit application.
TLG Managing Director Mark Thompson says the approval marks a major step in the company establishing its Swedish natural graphite anode production.
And lastly, Burley Minerals shares have dropped more than 4 per cent after launching a drilling program at its Chubb lithium project in Quebec.
The maiden program is set to include around 5000 metres of diamond core drilling to test lithium-bearing mineralisation in the central zone of its recently acquired project.
Burley Minerals was last trading at 23 cents.